

Supporting information

Design, Synthesis and Biological Evaluation 1*H*-pyrrolo[2,3-*b*] pyridine Derivatives as Potent Fibroblast Growth Factor Receptor Inhibitors



Xingping Su ^{a,†}, Zhihao Liu ^{a,†}, Lin Yue ^a, Xiuli Wu ^a, Wei Wei ^a, Hanyun Que ^a,
Tinghong Ye ^a, Yi Luo ^{b,*}, Yiwen Zhang ^{a,*}

^a *Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.*

^b *Department of Orthopedics, West China Hospital of Sichuan University, wai nan guo xue xiang 37#, 610041, Chengdu, Sichuan, China.*


Supporting chemistry Information:

3a:






13:49:46
190613_YLT_SXP_02 18 (0.308) Cm (4:24)

13-Jun-2019
TOF MS ES+
1.13e4





3b






3c





09:53:59
190627_YLT_SXP_S29 3 (0.051) Cm (2:24)

27-Jun-2019
TOF MS ES+
6.74e4




3d








14:05:10
190613_YLT_SXP_07 7 (0.120) Cm (1:24)

13-Jun-2019
TOF MS ES+
5.62e3




3e





14:00:47
190613_YLT_SXP_05 11 (0.188) Cm (1:24)

13-Jun-2019
TOF MS ES+
6.52e3




3f








09:51:59
190627_YLT_SXP_S28 6 (0.103) Cm (4:24)

27-Jun-2019
TOF MS ES+
3.66e4




3g



13:55:21
190613_YLT_SXP_03 13 (0.222) Cm (1:24)


13-Jun-2019
TOF MS ES+
6.44e4






3h

13:44:59
190613_YLT_SXP_01 22 (0.376) Cm (3:24)

13-Jun-2019
TOF MS ES+
3.07e4




3i






09:46:15
190627_YLT_SXP_S26 14 (0.239) Cm (1:23)

27-Jun-2019
TOF MS ES+
1.45e4





3j






3k




150.14
 144.08
 143.37
 140.46
 139.05
 131.67
 129.13
 126.24
 126.21
 125.06
 123.22
 121.63
 118.75
 117.58
 109.29
 108.00

69.88






14:02:59
190613_YLT_SXP_06 22 (0.376) Cm (1:24)

13-Jun-2019
TOF MS ES+
3.50e3





4a






4b





12:05:55
190620_YLT_SXP_S11 24 (0.411) Cm (1:24)

20-Jun-2019
TOF MS ES+
1.09e4




4c







10:04:31
190627_YLT_SXP_S33 15 (0.257) Cm (3:24)

27-Jun-2019
TOF MS ES+
1.01e4




4d





13:03:11
190620_YLT_SXP_S14 21 (0.359) Cm (1:24)

20-Jun-2019
TOF MS ES+
1.77e4




4e








12:59:14
190620_YLT_SXP_S12 5 (0.086) Cm (2.24)

20-Jun-2019
TOF MS ES+
3.47e3




4f





10:02:45
190627_YLT_SXP_S32 9 (0.154) Cm (4:24)

27-Jun-2019
TOF MS ES+
7.91e3




4g








14:12:49
190613_YLT_SXP_10 17 (0.291) Cm (1.24)

13-Jun-2019
TOF MS ES+
6.23e3




4h





14:07:01
190613_YLT_SXP_08 15 (0.257) Cm (4:24)

13-Jun-2019
TOF MS ES+
3.20e4




4i








09:58:32
190627_YLT_SXP_S30 8 (0.137) Cm (2:24)

27-Jun-2019
TOF MS ES+
5.11e4




4j





10:00:37
190627_YLT_SXP_S31 5 (0.086) Cm (3.24)

27-Jun-2019
TOF MS ES+
7.08e4




4k








13:01:03
190620_YLT_SXP_S13 21 (0.359) Cm (1:24)

20-Jun-2019
TOF MS ES+
3.10e3





13:05:39

190620_YLT_SXP_S19 22 (0.376) Cm (4:23)

20-Jun-2019

TOF MS ES+
1.69e5

